Abstracts tagged "Biomarkers and epigenetics"

Abstract Number: 2804 • 2015 ACR/ARHP Annual Meeting
The Global miRNA Whole Blood Profile of Ankylosing Spondylitis
Carolina Mejia Otero¹, Shervin Assassi¹, Michael H. Weisman², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Minghua Wu¹, John Hagan⁶, John D. Reveille⁷ and Gloria Salazar¹, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Neurosurgery, University of Texas at Houston, Houston, TX, ⁷Internal Medicine/Rheumatology, University of Texas Medical School at Houston, Houston, TX
Background/Purpose: MicroRNA (miRNA) are small non-coding RNAs that play an important role in posttranscriptional gene regulation and their involvement in the pathophysiology of several autoimmune…
Abstract Number: 2594 • 2012 ACR/ARHP Annual Meeting
Epigenetic Signature of the Response to Anti-TNF in Juvenile Idiopathic Arthritis
Roberto Spreafico¹, Maura Rossetti¹, Hong Zhang¹, Maryam Moshref¹, Carol Wallace², D. J. Lovell³ and Salvatore Albani⁴, ¹Translational Immunology, Sanford-Burnham Medical Research Institute, La Jolla, CA, ²Div Rheumatology-Pediatrics, Childrens Hosp & Regional Med, Seattle, WA, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Translational Research Program, Infectious and Inflammatory Diseases, Sanford-Burnham Medical Research Institute, La Jolla, CA
Background/Purpose: The identification of prognostic markers of responsiveness to the therapy in JIA would not only radically improve clinical management, but also shed light on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].